Clinical trial NCT02105116: AML Therapy With Irradiated Allogeneic Cells
Official title: AML Therapy With Irradiated Allogeneic Cells
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Recurrent Adult Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia
Lead sponsor: Rutgers, The State University of New Jersey
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
name: Rutgers Cancer Institute of New Jersey
First posted: 2014-04-07
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This pilot clinical trial studies if cells donated by a close genetic relative can help maintain acute myeloid leukemia (AML) complete remission (CR). Eligible patients will receive a standard induction chemotherapy. If a complete remission results they will receive irradiated allogeneic cells from a HLA haploidentical relative. Only patients who obtain a CR after the standard induction chemotherapy are eligible for the experimental therapy (irradiated haploidentical cells).

Detailed description: PRIMARY OBJECTIVES:

I. Toxicity of haploidentical allogeneic cellular therapy in patients in complete remission (CR) (or CR with incomplete platelet recovery \[CRp\]) after induction chemotherapy with fludarabine (fludarabine phosphate)-cytarabine.

II. Efficacy of haploidentical allogeneic cellular therapy in patients in CR (or CRp) after induction chemotherapy with fludarabine-cytarabine (remission rates at 6, 12, 18, 24 months).

SECONDARY OBJECTIVES:

I. Immunologic parameters before and after haploidentical therapy: host anti-leukemia T cells; host regulatory T cells.

OUTLINE:

INDUCTION CHEMOTHERAPY: Patients receive fludarabine phosphate intravenously (IV) over 1 hour once daily (QD) for 5 days and cytarabine IV over 4 hours for 5 days. Treatment may continue for 1 or 2 courses at the discretion of the treating physician.

ALLOGENEIC CELLULAR THERAPY: Patients undergo irradiated donor lymphocyte infusion (DLI) of 3 x 10\^8 cluster of differentiation (CD)3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically for up to 2 years.

Eligibility criteria: Inclusion Criteria:

* Histologically proven non-M3 AML:

  * Refractory/relapsed AML OR
  * Initial diagnosis of AML in patient \>= 60 years old
* Total bilirubin =\< 1.5 times upper limit of normal (ULN) institutional limits (unless Gilbert's disease)
* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X institutional ULN
* Cardiac left ventricular ejection fraction (LVEF) \>= 35%
* Serum creatinine =\< 1.5 mg/dl
* Any organ dysfunction thought to be secondary to disease will be considered separately and the patient will be included at the investigators discretion
* Patients must give informed consent
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 3
* Must have a potential haploidentical donor (parent, sibling, child)
* A patient is eligible for second enrollment (allo-cellular therapy) if all of the following inclusion criteria are met:
* Patient must have documented CR or CRp after 1 or 2 cycles of fludarabine + cytarabine
* Patient must not be a candidate for an allo-hematopoietic stem cell transplant (HSCT)
* Patient must have a partially (\>= 3/6 class I antigen) human leukocyte antigen (HLA)-matched (by serology or low resolution deoxyribonucleic acid \[DNA\] testing) relative able to serve as a donor
* Patients must not have active uncontrolled infections, other medical or psychological/social conditions that might increase the likelihood of patient adverse effects or poor outcomes
* Total bilirubin \< 1.5 times upper limit of normal (ULN) institutional limits (unless Gilbert's disease)
* AST(SGOT)/ALT(SGPT) =\< 2.5 X institutional ULN
* Serum creatinine \< 2.0 mg/dl
* ECOG performance status =\< 2
* DONOR: donor must be related to patient and be partially (\>= 3/6 antigen) HLA-matched
* DONOR: donor must meet all New Brunswick Affiliated Hospitals (NBAH) requirements for hematopoietic stem cell donation, including:
* DONOR: age \>= 18 years old
* DONOR: white blood cells (WBC) 4.0-10.0 x 10\^3/mm\^3
* DONOR: platelet count 150,000 to 440,000/mm\^3
* DONOR: hemoglobin/hematocrit; 12.5-18 g/dl, 38 to 54%
* DONOR: not pregnant or lactating
* DONOR: not human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV), hepatitis B core or human T-lymphotropic virus (HTLV)-I/II seropositive; hepatitis B surface antigen (HB S ag) (-); meet other infectious disease screening criteria utilized by NBAH Blood Center
* DONOR: no uncontrolled infections, other medical or psychological/social conditions, or medications that might increase the likelihood of patient or donor adverse effects or poor outcomes
* DONOR: meet other blood bank criteria for blood product donation (as determined by NBAH Blood Center screening history and laboratory studies)

Exclusion Criteria:

* History of current or prior medical problems that the investigator feels will prevent administration of therapy or assessment of response due to excess toxicity
* Patients with known active central nervous system (CNS) leukemia will be excluded from this clinical study
* Known HIV-positive patients are excluded from the study
* Patients may not be pregnant or breast feeding

Primary outcomes:
measure: Adverse Events Related to Experimental Therapy
timeFrame: Up to 2 years
measure: Response Rate, Determined by Allogeneic Cell Therapy-related Mortality
timeFrame: Up to 2 years
measure: Response Rate, Determined by Duration of Complete Remission
timeFrame: Up to 2 years
Secondary outcomes:
measure: Progression Free Survival Probability for CR
timeFrame: At 2 years
Other outcomes:
Locations:
city: New Brunswick
country: United States
facility: Rutgers Cancer Institute of New Jersey
state: New Jersey
Study officials:
affiliation: Rutgers Cancer Institute of New Jersey
name: Roger Strair, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: